Technical Analysis for XAIR - Beyond Air, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.11 | 0.91% | 0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 0.91% | |
| Wide Bands | Range Expansion | 0.91% | |
| Down 3 Days in a Row | Weakness | 0.91% | |
| Down 4 Days in a Row | Weakness | 0.91% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 3 days ago |
| Down 3% | 3 days ago |
| Fell Below Previous Day's Low | 3 days ago |
| Up 2% | 3 days ago |
| Up 1% | 3 days ago |
Get a Trading Sidekick!
- Earnings date: 06/20/2024
Beyond Air, Inc. Description
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The Beyond Air NO Delivery System can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM).
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Medicine Biopharmaceutical Hypertension Coronavirus Bacterial Disease Pulmonary Hypertension Tuberculosis Bacteriology Lung Infection Nontuberculous Mycobacteria Lower Respiratory Tract Infection Lung Infections Mycobacterium Respiratory And Other Diseases Respiratory Tract Respiratory Tract Infection
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.36 |
| 52 Week Low | 1.06 |
| Average Volume | 311,948 |
| 200-Day Moving Average | 1.93 |
| 50-Day Moving Average | 1.37 |
| 20-Day Moving Average | 1.21 |
| 10-Day Moving Average | 1.22 |
| Average True Range | 0.13 |
| RSI (14) | 39.76 |
| ADX | 12.9 |
| +DI | 18.84 |
| -DI | 21.19 |
| Chandelier Exit (Long, 3 ATRs) | 1.02 |
| Chandelier Exit (Short, 3 ATRs) | 1.45 |
| Upper Bollinger Bands | 1.40 |
| Lower Bollinger Band | 1.02 |
| Percent B (%b) | 0.22 |
| BandWidth | 31.36 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.0016 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.20 | ||||
| Resistance 3 (R3) | 1.19 | 1.16 | 1.18 | ||
| Resistance 2 (R2) | 1.16 | 1.13 | 1.16 | 1.17 | |
| Resistance 1 (R1) | 1.13 | 1.12 | 1.14 | 1.14 | 1.17 |
| Pivot Point | 1.10 | 1.10 | 1.10 | 1.10 | 1.10 |
| Support 1 (S1) | 1.07 | 1.07 | 1.08 | 1.08 | 1.04 |
| Support 2 (S2) | 1.04 | 1.06 | 1.04 | 1.04 | |
| Support 3 (S3) | 1.01 | 1.04 | 1.03 | ||
| Support 4 (S4) | 1.02 |
